[논문]Next Generation Antiobesity Medications: Setmelanotide, Semaglutide, Tirzepatide and Bimagrumab: What do They Mean for Clinical Practice?

Ryan, Donna H.

doi:10.7570/jomes21033

Next Generation Antiobesity Medications: Setmelanotide, Semaglutide, Tirzepatide and Bimagrumab: What do They Mean for Clinical Practice? 원문보기

Journal of obesity & metabolic syndrome, v.30 no.3, 2021년, pp.196 - 208

Ryan, Donna H. (Pennington Biomedical Research Center, Baton Rouge, LA, USA)

Abstract ▼ AI-Helper

There is a new generation of antiobesity drugs in development or just arriving on the scene. First, setmelanotide has been approved for three of the ultrarare genetic conditions that cause obesity–pro-opiomelanocortin deficiency, proprotein convertase subtilisin and kexin type 1 (an important enzyme in the melanocortin pathway) and leptin receptor deficiency. Setmelanotide marks the first in a personalized medicine approach to obesity. Second, semaglutide 2.4 mg once weekly has been submitted to regulators in the United States and the European Union for approval for patients with obesity (body mass index [BMI] ≥30 kg/m2) or overweight (BMI ≥27 kg/m2) and at least one weight related comorbidity. This drug has been studied in five phase 3 clinical trials, four discussed herein: semaglutide produces roughly twice as much weight loss as we have seen in older antiobesity medications. Semaglutide is already in use for treatment of diabetes and, as a glucagon-like peptide 1 (GLP-1) receptor analog, is part of a class of drugs used widely in diabetes. Tirzepatide, a glucose-insulin peptide and GLP-1 dual agonist is in phase 3 study for obesity management, and bimagrumab is a new agent in phase 2 with a unique mechanism of action; they are generating much interest. The purpose of this narrative review is lay the groundwork for a discussion of the clinical impact of these new medications on the clinical practice of obesity. Further, these developments shall be used to launch a speculation of what is likely to be their impact on the future of obesity pharmacotherapy.

주제어

참고문헌 (40)

1 Sharma S Garfield AS Shah B Kleyn P Ichetovkin I Moeller IH 2019 Current mechanistic and pharmacodynamic understanding of melanocortin-4 receptor activation Molecules 24 1892 10.3390/molecules24101892 31100979

상세보기
2 Kievit P Halem H Marks DL Dong JZ Glavas MM Sinnayah P 2013 Chronic treatment with a melanocortin-4 receptor agonist causes weight loss, reduces insulin resistance, and improves cardiovascular function in diet-induced obese rhesus macaques Diabetes 62 490 7 10.2337/db12-0598 23048186

상세보기
3 Collet TH Dubern B Mokrosinski J Connors H Keogh JM Mendes de Oliveira E 2017 Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency Mol Metab 6 1321 9 10.1016/j.molmet.2017.06.015 29031731

상세보기
4 Kühnen P Clément K Wiegand S Blankenstein O Gottesdiener K Martini LL 2016 Proopiomelanocortin deficiency treated with a melanocortin-4 receptor agonist N Engl J Med 375 240 6 10.1056/NEJMoa1512693 27468060

상세보기
5 Haws R Brady S Davis E Fletty K Yuan G Gordon G 2020 Effect of setmelanotide, a melanocortin-4 receptor agonist, on obesity in Bardet-Biedl syndrome Diabetes Obes Metab 22 2133 40 10.1111/dom.14133 32627316

상세보기
6 Ayers KL Glicksberg BS Garfield AS Longerich S White JA Yang P 2018 Melanocortin 4 receptor pathway dysfunction in obesity: patient stratification aimed at MC4R agonist treatment J Clin Endocrinol Metab 103 2601 12 10.1210/jc.2018-00258 29726959

상세보기
7 Clément K Biebermann H Farooqi IS Van der Ploeg L Wolters B Poitou C 2018 MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency Nat Med 24 551 5 10.1038/s41591-018-0015-9 29736023

상세보기
8 Wikimedia Commons Contributors 2020 "File:Setmelanotide.svg [Internet] Wikimedia Commons, the free media repository Available from: https://commons.wikimedia.org/w/index.php?title=File:Setmelanotide.svg&oldid=467575939 cited 2021 Sep 17
9 Echemi 2020 Lilly's GLP-1 and Tirzepatide initiates phase III clinical trial [Internet] Echemi Available from: https://www.echemi.com/cms/110494.html cited 2021 Sep 17
10 RCSB Protein Data Bank 2017 Biological assembly 1 of bimagrumab [Internet] RCSB Protein Data Bank Available from: https://www.rcsb.org/structure/5nhw cited 2021 Sep 17
11 U.S. Food and Drug Administration 2020 FDA approves first treatment for weight management for people with certain rare genetic conditions [Internet] U.S. Food and Drug Administration Silver Spring (MD) Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-first-treatment-weight-management-people-certain-rare-genetic-conditions cited 2021 Mar 18
12 BioWorld 2020 Rhythm wins first FDA approval for obesity drug Imcivree [Internet] BioWorld Available from: https://www.bioworld.com/articles/500740-rhythm-wins-first-fda-approval-for-obesity-drug-imcivree?v=preview cited 2021 Mar 18
13 Clément K van den Akker E Argente J Bahm A Chung WK Connors H 2020 Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials Lancet Diabetes Endocrinol 8 960 70 10.1016/S2213-8587(20)30364-8 33137293

상세보기
14 Ayers KL Glicksberg BS Garfield AS Longerich S White JA Yang P 2018 Melanocortin 4 receptor pathway dysfunction in obesity: patient stratification aimed at MC4R agonist treatment J Clin Endocrinol Metab 103 2601 12 10.1210/jc.2018-00258 29726959

상세보기
15 Pearson S Kietsiriroje N Ajjan RA 2019 Oral semaglutide in the management of type 2 diabetes: a report on the evidence to date Diabetes Metab Syndr Obes 12 2515 29 10.2147/DMSO.S229802 31819577
16 Ryan D Acosta A 2015 GLP-1 receptor agonists: nonglycemic clinical effects in weight loss and beyond Obesity (Silver Spring) 23 1119 29 10.1002/oby.21107 25959380

상세보기
17 Marso SP Bain SC Consoli A Eliaschewitz FG Jódar E Leiter LA 2016 Semaglutide and cardiovascular outcomes in patients with type 2 diabetes N Engl J Med 375 1834 44 10.1056/NEJMoa1607141 27633186

상세보기
18 O'Neil PM Birkenfeld AL McGowan B Mosenzon O Pedersen SD Wharton S 2018 Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial Lancet 392 637 49 10.1016/S0140-6736(18)31773-2 30122305

상세보기
19 Kushner RF Calanna S Davies M Dicker D Garvey WT Goldman B 2020 Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5 Obesity (Silver Spring) 28 1050 61 10.1002/oby.22794 32441473

상세보기
20 Wilding JP Batterham RL Calanna S Davies M Van Gaal LF Lingvay I 2021 Once-weekly semaglutide in adults with overweight or obesity N Engl J Med 384 989 1002 10.1056/NEJMoa2032183 33567185

상세보기
21 Davies M Færch L Jeppesen OK Pakseresht A Pedersen SD Perreault L 2021 Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial Lancet 397 971 84 10.1016/S0140-6736(21)00213-0 33667417

상세보기
22 Wadden TA Bailey TS Billings LK Davies M Frias JP Koroleva A 2021 Effect of Subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial JAMA 325 1403 13 10.1001/jama.2021.1831 33625476

상세보기
23 Rubino D Abrahamsson N Davies M Hesse D Greenway FL Jensen C 2021 Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial JAMA 325 1414 25 10.1001/jama.2021.3224 33755728

상세보기
24 Wadden TA West DS Delahanty L Jakicic J Rejeski J Look AHEAD Research Group 2006 The Look AHEAD study: a description of the lifestyle intervention and the evidence supporting it Obesity (Silver Spring) 14 737 52 10.1038/oby.2006.84 16855180

상세보기
25 Heymsfield SB Gonzalez MC Shen W Redman L Thomas D 2014 Weight loss composition is one-fourth fat-free mass: a critical review and critique of this widely cited rule Obes Rev 15 310 21 10.1111/obr.12143 24447775

상세보기
26 Wing RR Look AHEAD Research Group 2021 Does lifestyle intervention improve health of adults with overweight/obesity and type 2 diabetes? Findings from the look AHEAD randomized trial Obesity (Silver Spring) 29 1246 58 10.1002/oby.23158 33988896

상세보기
27 Pilitsi E Farr OM Polyzos SA Perakakis N Nolen-Doerr E Papathanasiou AE 2019 Pharmacotherapy of obesity: available medications and drugs under investigation Metabolism 92 170 92 10.1016/j.metabol.2018.10.010 30391259

상세보기
28 Ryan DH Lingvay I Colhoun HM Deanfield J Emerson SS Kahn SE 2020 Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design Am Heart J 229 61 9 10.1016/j.ahj.2020.07.008 32916609

상세보기
29 Ryan DH Yockey SR 2017 Weight loss and improvement in comorbidity: differences at 5%, 10%, 15%, and over Curr Obes Rep 6 187 94 10.1007/s13679-017-0262-y 28455679

상세보기
30 Magkos F Fraterrigo G Yoshino J Luecking C Kirbach K Kelly SC 2016 Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity Cell Metab 23 591 601 10.1016/j.cmet.2016.02.005 26916363

상세보기
31 Friedrichsen M Breitschaft A Tadayon S Wizert A Skovgaard D 2021 The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity Diabetes Obes Metab 23 754 62 10.1111/dom.14280 33269530

상세보기
32 Frias JP Nauck MA Van J Kutner ME Cui X Benson C 2018 Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial Lancet 392 2180 93 10.1016/S0140-6736(18)32260-8 30293770

상세보기
33 ClinicalTrial.gov 2019 A study of tirzepatide (LY3298176) in participants with obesity or overweight (SURMOUNT-1) [Internet] U.S. National Library of Medicine Bethesda (MD) Available from: https://clinicaltrials.gov/ct2/show/NCT04184622 cited 2021 Mar 18
34 Min T Bain SC 2021 The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: the SURPASS clinical trials Diabetes Ther 12 143 57 10.1007/s13300-020-00981-0 33325008

상세보기
35 Eli Lilly and Company 2021 Tirzepatide achieved superior A1C and body weight reductions across all three doses compared to injectable semaglutide in adults with type 2 diabetes [Internet] Lilly Indianapolis (IL) Available from: Investor.lilly.com/news-releases/news-releasedetails/tirzepatide-achieved-superior-a1c-and-body-weight-reductions
36 Fournier B Murray B Gutzwiller S Marcaletti S Marcellin D Bergling S 2012 Blockade of the activin receptor IIb activates functional brown adipogenesis and thermogenesis by inducing mitochondrial oxidative metabolism Mol Cell Biol 32 2871 9 10.1128/MCB.06575-11 22586266

상세보기
37 Rooks DS Laurent D Praestgaard J Rasmussen S Bartlett M Tankó LB 2017 Effect of bimagrumab on thigh muscle volume and composition in men with casting-induced atrophy J Cachexia Sarcopenia Muscle 8 727 34 10.1002/jcsm.12205 28905498

상세보기
38 Heymsfield SB Coleman LA Miller R Rooks DS Laurent D Petricoul O 2021 Effect of bimagrumab vs placebo on body fat mass among adults with type 2 diabetes and obesity: a phase 2 randomized clinical trial JAMA Netw Open 4 e2033457 10.1001/jamanetworkopen.2020.33457 33439265

상세보기
39 Srivastava G Apovian C 2018 Future pharmacotherapy for obesity: new anti-obesity drugs on the horizon Curr Obes Rep 7 147 61 10.1007/s13679-018-0300-4 29504049

상세보기
40 Rebello CJ Greenway FL 2020 Obesity medications in development Expert Opin Investig Drugs 29 63 71 10.1080/13543784.2020.1705277 31847611

상세보기

표제어: PCR

동의어: Packet Collision Rate

용어 설명 출처 목록 (6)

용어 설명: PCR은 세균 특이성이 있는 primer를 이용하여 적은 수의 세균이 있을지라도 쉽게 검출할 수 있는 유용한 방법이며, 이를 이용하여 구강 내 치면세균막이나 타액에서 직접 세균을 검출할 수 있게 되었다[8].

내보내기 구분	파일저장 인쇄 메일전송
구성항목	기본정보 상세정보 관리번호, 논문명, 저널/프로시딩명, 저자 , 발행년, 권, 호, 시작페이지, 끝페이지, 발행기관 관리번호, 논문명, 대등논문명, 저자 , 저널/프로시딩명, 발행기관, 발행년, 발행언어, 권, 호, 시작페이지, 끝페이지, ISBN, ISSN, 주제분야, 키워드, 초록(한글), 초록(영문), 저자(소속기관)
저장형식	Text(ASCII format) Excel format RefWorks Direct Export RIS format (for Reference Manager, ProCite, EndNote), Scholar's Aids, Mendeley
메일정보	받는사람 (필수) @ 보내는사람 (선택) @ 제목 내용 KISTI 검색결과 이메일 서비스
안내	총 건의 자료가 검색되었습니다. 다운받으실 자료의 인덱스를 입력하세요. (1-10,000) 검색결과의 순서대로 최대 10,000건 까지 다운로드가 가능합니다. 데이타가 많을 경우 속도가 느려질 수 있습니다.(최대 2~3분 소요) 다운로드 파일은 UTF-8 형태로 저장됩니다. 파일의 내용이 제대로 보이지 않을실 때는 웹브라우저 상단의 보기 -> 인코딩 -> 자동선택 여부를 확인하십시오. ~ Text(ASCII format) Excel format

연합인증

Next Generation Antiobesity Medications: Setmelanotide, Semaglutide, Tirzepatide and Bimagrumab: What do They Mean for Clinical Practice? 원문보기

Abstract ▼ AI-Helper

주제어

참고문헌 (40)

이 논문을 인용한 문헌

관련 콘텐츠

원문 보기

원문 URL 링크

오픈액세스(OA) 유형

이 논문과 함께 이용한 콘텐츠

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

선택된 텍스트